Singh Biotechnology has a strong USA and worldwide patent position surrounding our novel technology platform of single domain antibody’s regarding discovery, development, and clinical use of its therapeutics.
Our scientific expertise and experience combined with its patent portfolio puts the company in a unique position to leverage its single domain antibody technology platform to target multiple disease indications.
Singh Biotechnology has positioned itself to be the first company to discover and develop first-in-class therapeutics the specifically target intracellular proteins for diseases.
For more information on Singh Biotechnology’s IP portfolio, please contact ssingh@singhbiotechnology.com